| Patent application number | Description | Published |
|---|
| 20090042918 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 - Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R | 02-12-2009 |
| 20090156576 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 06-18-2009 |
| 20090215803 | Pyrimidinones as Casein Kinase II (CK2) Modulators - A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R | 08-27-2009 |
| 20090247559 | Benzofuropyrimidinones - A compound according to formula I: | 10-01-2009 |
| 20090298830 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use - This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R | 12-03-2009 |
| 20100135954 | 6-Phenylpyrimidinones as PIM Modulators - A compound having Formula I or II (Formula I) or (Formula II), or a pharmaceutically acceptable salt thereof, wherein X, Z, R | 06-03-2010 |
| 20100144770 | Pyrimidinones as Casein Kinase II (CK2) Modulators - A compound having Formula I: or a pharmaceutically acceptable salt thereof, wherein X, R, R and R are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. The compounds of Formula I are inhibitors of Casein kinase II (CK2) pathways. | 06-10-2010 |
| 20100249096 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 09-30-2010 |
